CD166/ALCAM Expression Is Characteristic of Tumorigenicity and Invasive and Migratory Activities of Pancreatic Cancer Cells
Year: 2014
Type: article
Abstract: BACKGROUND: CD166, also known as activated leukocyte cell adhesion molecule (ALCAM), is expressed by various cells in several tissues including cancer. However, the role of CD166 in malignant tumors is controversial, especially in pancreatic cancer. This study aimed to clarify the role and significance of CD166 expression in pancreatic cancer. METHODS: We performed immunohistochemistry and flow cytometry to analyze the expression of CD166 in surgical pancreatic tissues and pancreatic cancer cell lines. The differences between isolated CD166+ and CD166- pancreatic cancer cells were analyzed by invasion and migration assays, and in mouse xenograft models. We also performed quantitative RT-PCR and microarray analyses to evaluate the expression levels of CD166 and related genes in cultured cells. RESULTS: Immunohistochemistry revealed high expression of CD166 in pancreatic cancer tissues (12.2%; 12/98) compared with that in normal pancreas controls (0%; 0/17) (p = 0.0435). Flow cytometry indicated that CD166 was expressed in 33.8-70.2% of cells in surgical pancreatic tissues and 0-99.5% of pancreatic cancer cell lines. Invasion and migration assays demonstrated that CD166- pancreatic cancer cells showed stronger invasive and migratory activities than those of CD166+ cancer cells (p<0.05). On the other hand, CD166+ Panc-1 cells showed a significantly stronger colony formation activity than that of CD166- Panc-1 cells (p<0.05). In vivo analysis revealed that CD166+ cells elicited significantly greater tumor growth than that of CD166- cells (p<0.05) in both subcutaneous and orthotopic mouse tumor models. mRNA expression of the epithelial-mesenchymal transition activator Zeb1 was over-expressed in CD166- cells (p<0.001). Microarray analysis showed that TSPAN8 and BST2 were over-expressed in CD166+ cells, while BMP7 and Col6A1 were over-expressed in CD166- cells. CONCLUSIONS: CD166+ pancreatic cancer cells are strongly tumorigenic, while CD166- pancreatic cancer cells exhibit comparatively stronger invasive and migratory activities. These findings suggest that CD166 expression is related to different functions in pancreatic cancer cells.
Source: PLoS ONE
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,382
Awards: Identifying the leading cell for the invasion of pancreatic cancer, Identification of the key stromal cell responsible for desmoplasia of pancreatic cancer, elucidation of the origin of it, and regulation of its function, G3296525006, Functional analysis and regulation of microvesicles that affect tumor-stromal interaction in pancreatic cancer., Development of nanocapsule containing MRI contrast agent effective for early diagnosis of pancreatic cancer, New development in the study of tumor-stromal interaction focused on extracellular miRNA via exosome., Elucidation of leading cell and cancer microenvironment normalization of pancreatic cancer, 膵癌間質相互作用に寄与する膵星細胞の同定と特異的分子標的治療の開発, Establishment of a novel therapeutic strategy for pancreatic cancer phenotyping and regulating the pancreatic stellate cells in the tumor microenvironment, Biological and clinical significance of niche during carcinogenesis in pancreatic cancer, A new strategy for improving the efficacy of the conventional therapy of pancreatic cancer by remodeling its microenvironment, Normalization of tumor vessels targeting pericytes; a new approach in treatment of pancreatic cancer, Early detection of pancreatic ductal adenocarcinoma based on the molecular assessment of pancreatic ductal adenocarcinoma concomitant with IPMN of the pancreas., Management of pancreatic cancer liver metastasis through investigating the mechanism of formation and remodeling its microenvironment.
OpenAlex ID: W1964035033